Ratings Moves: AIR,...
Health Care: Drugs
AcelRx Pharmaceuticals Inc. (ACRX: NASDAQ)
$6.68 -0.51 | -7.09%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.68 |
| 52 Week High | 7.30 |
| 52 Week Low | 2.27 |
| Avg. Daily Vol. (Mil) | 0.30 |
| Beta (3 year) | 1.63 |
| Share Related Items | |
| Mkt Cap (Mil) | 248.75 |
| Shares Out (Mil) | 37.24 |
| Float (Mil) | 14.04 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.20 |
| Current Ratio | 3.40 |
| LT Debt/ Equity | 0.30 |
| Total Debt / Equity | 0.65 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 82.78 |
| Price/Book | 11.35 |
| Price/Cash Flow | -4.70 |
| Per Share Data | |
| Earnings | -1.49 |
| Sales | 0.08 |
| Book Value | 0.59 |
| Cash Flow | -1.41 |
| Business Summary | |
|---|---|
| General Information | |
| 575 Chesapeake Drive
Redwood City, CA 94063 |
|
| www.acelrx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 25 | |
| CEO: Mr. Richard A. King | |
| Short Interest | |
| Current Month (Mil) | 1.50 |
| Previous Month (Mil) | 1.46 |
| Short Interest Ratio (Days) | 5.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -100.60 |
| Return on Investments | -187.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ACRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
Latest ACRX Headlines from TheStreet
- 4 Biotech Stocks Under $10 Making Big Moves 04.09.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- 5 Stocks Insiders Are Stuffing in Their Stockings 12.12.12 | 12:12 pm
- Dunkin' Brands Prices IPO Above Range 07.26.11 | 07:07 pm
- IPO Lessons From Pandora 02.16.11 | 01:02 pm
- IPO Watch: 2011 02.16.11 | 01:02 pm
- Gaskins Warns on Speculative Pharma IPOs
02.02.11 | 08:02 am
Press Releases for ACRX
- AcelRx Pharmaceuticals To Present At The UBS Global Healthcare Conference - PR Newswire 05.16.13 | 03:05 pm
- AcelRx Pharmaceuticals To Hold First Quarter 2013 Financial Results Conference Call And Webcast On May 8, 2013 - PR Newswire 05.03.13 | 07:05 am
- AcelRx Pharmaceuticals Presents Positive Clinical Data For The Sufentanil NanoTab PCA System At ASRA Medical Meeting - PR Newswire 05.02.13 | 07:05 am
- Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint In Dose-Finding Phase 2 Clinical Trial - PR Newswire 04.24.13 | 07:04 am
- AcelRx Pharmaceuticals To Hold Fourth Quarter 2012 Financial Results Conference Call And Webcast On March 12, 2013 - PR Newswire 03.07.13 | 07:03 am
- AcelRx Top-line Data Show Primary Endpoint Achieved In Pivotal Phase 3 Study Of Sufentanil NanoTab PCA System For Post-Operative Pain In Major Open Abdominal Surgery Patients - PR Newswire 03.04.13 | 06:03 pm
- AcelRx Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.27.13 | 07:02 am
- AcelRx Pharmaceuticals Provides Clinical Trial Updates - PR Newswire 02.19.13 | 07:02 am
- AcelRx Appoints Adrian Adams To Board Of Directors As Chairman - PR Newswire 02.12.13 | 07:02 am
- AcelRx Pharmaceuticals Announces Exercise Of Option To Purchase Additional Shares - PR Newswire 12.14.12 | 12:12 pm
Partner Headlines for ACRX
- UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01 - Benzinga 04.08.13 | 09:04 am
- After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP - NASDAQ 03.12.13 | 06:03 pm
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts - Seeking Alpha 12.22.12 | 09:12 am
- FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain - Benzinga 11.15.12 | 08:11 am
- New IPO Filings And What's On The Horizon - Seeking Alpha 02.03.12 | 06:02 pm
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
